您的位置：首页 > 产品中心 > 117621-64-4， ICI 192605
ICI 192605
产品别名
117621-64-4
ICI 192605
(4Z)-rel-
4(Z)-6-(2-o-chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl) hexenoic acid
4-Hexenoic acid
6-[(2R,4R,5S)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C22H23ClO5 |
| Molecular weight | 402.87 |
| MDL number | MFCD00673936 |
| PubChem Substance ID【PubChem化学物质编号】 | 329815367 |
| Biochem/physiol Actions【生化/生理作用】 | ICI 192605 is a potent thromboxane A2 receptor antagonist. It inhibits platelet aggregation and can reverse the effects of vasoconstrictors such as TXA2 or PGD2. ICI 192605 can reverse vasoconstriction induced by inhibition of NO production by L-NEMA, which leads to an increase in TXA2 release. |
| Features and Benefits【特点和优势】 | This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here. This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here. |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| color【颜色】 | white to tan |
| solubility【溶解性】 | DMSO: ≥20 mg/mL |
| originator【创始人】 | AstraZeneca |
| storage temp.【储存温度】 | −20℃ |
| SMILES string | OC(=O)CC\C=C/C[C@H]1CO[C@H](O[C@H]1c2ccccc2O)c3ccccc3Cl |
| InChI | 1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m0/s1 |
| InChI key | WHUIENZXNGAHQI-YGPRPMEGSA-N |
| packaging【包装】 | 5, 25 mg in glass bottle |
安全信息
| Pictograms【象形图】 | GHS07,GHS09 |
| Signal word【警示用语：】 | Warning |
| Hazard Statements | H302 - H410 |
| Precautionary Statements | P273 - P501 |
| Hazard Classifications【危险分类】 | Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 |
| Storage Class Code【储存分类代码】 | 11 - Combustible Solids |
| WGK | WGK 3 |
